Email ID
Sign me in automatically next time
Lilly EXPEDITION data puts some flesh on solanezumab's bones

The full data from Lilly's mixed EXPEDITION studies for its anti-amyloid Alzheimer's disease monoclonal antibody (MAb) candidate solanezumab have now been presented, bringing some clarity on the...
09 October 2012
Alex Shimmings

Please Login to read the full article.
04 April 2016
Stockholm, Sweden
06 April 2016
Hamburg, Germany
JOB OF THE WEEK Promote your job vacancy
© 2016 Informa plc. All rights reserved.
This site is owned and operated by Informa plc ("Informa") whose registered office is Mortimer House, 37-41 Mortimer Street, London, W1T 3JH. Registered in England and Wales. Number 3099067. UK VAT Group: GB 365 4626 36